Biotechnology
Compare Stocks
5 / 10Stock Comparison
MDXG vs NAUT vs CDNA vs OSUR vs ILMN
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Diagnostics & Research
Medical - Instruments & Supplies
Medical - Diagnostics & Research
MDXG vs NAUT vs CDNA vs OSUR vs ILMN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Medical - Diagnostics & Research | Medical - Instruments & Supplies | Medical - Diagnostics & Research |
| Market Cap | $548M | $366M | $1.11B | $225M | $21.07B |
| Revenue (TTM) | $389M | $0.00 | $413M | $85M | $4.39B |
| Net Income (TTM) | $31M | $-57M | $-8M | $-53M | $853M |
| Gross Margin | 81.0% | — | 48.2% | 38.8% | 67.1% |
| Operating Margin | 10.2% | — | -3.3% | -58.6% | 20.9% |
| Forward P/E | 295.2x | — | 22.8x | — | 26.8x |
| Total Debt | $23M | $30M | $20M | $13M | $2.55B |
| Cash & Equiv. | $166M | $12M | $65M | $199K | $1.42B |
MDXG vs NAUT vs CDNA vs OSUR vs ILMN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Aug 20 | May 26 | Return |
|---|---|---|---|
| MiMedx Group, Inc. (MDXG) | 100 | 54.3 | -45.7% |
| Nautilus Biotechnol… (NAUT) | 100 | 26.9 | -73.1% |
| CareDx, Inc (CDNA) | 100 | 62.8 | -37.2% |
| OraSure Technologie… (OSUR) | 100 | 26.7 | -73.3% |
| Illumina, Inc. (ILMN) | 100 | 40.0 | -60.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MDXG vs NAUT vs CDNA vs OSUR vs ILMN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MDXG has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.
- beta 1.22
- Rev growth 20.0%, EPS growth 14.3%, 3Y rev CAGR 16.1%
- Lower volatility, beta 1.22, Low D/E 8.8%, current ratio 4.32x
- Beta 1.22, current ratio 4.32x
NAUT ranks third and is worth considering specifically for momentum.
- +311.5% vs MDXG's -47.1%
CDNA is the clearest fit if your priority is value.
- Lower P/E (22.8x vs 26.8x)
Among these 5 stocks, OSUR doesn't own a clear edge in any measured category.
ILMN is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 0.7% 10Y total return vs MDXG's -48.5%
- 19.4% margin vs OSUR's -61.9%
- 13.4% ROA vs NAUT's -29.2%, ROIC 16.8% vs -26.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.0% revenue growth vs OSUR's -38.1% | |
| Value | Lower P/E (22.8x vs 26.8x) | |
| Quality / Margins | 19.4% margin vs OSUR's -61.9% | |
| Stability / Safety | Beta 1.22 vs NAUT's 1.82, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +311.5% vs MDXG's -47.1% | |
| Efficiency (ROA) | 13.4% ROA vs NAUT's -29.2%, ROIC 16.8% vs -26.0% |
MDXG vs NAUT vs CDNA vs OSUR vs ILMN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
MDXG vs NAUT vs CDNA vs OSUR vs ILMN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MDXG leads in 2 of 6 categories
ILMN leads 1 • CDNA leads 1 • NAUT leads 0 • OSUR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ILMN leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ILMN and NAUT operate at a comparable scale, with $4.4B and $0 in trailing revenue. ILMN is the more profitable business, keeping 19.4% of every revenue dollar as net income compared to OSUR's -61.9%. On growth, CDNA holds the edge at +39.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $389M | $0 | $413M | $85M | $4.4B |
| EBITDAEarnings before interest/tax | $53M | -$58M | $2M | -$45M | $1.1B |
| Net IncomeAfter-tax profit | $31M | -$57M | -$8M | -$53M | $853M |
| Free Cash FlowCash after capex | $66M | -$51M | $65M | -$33M | $989M |
| Gross MarginGross profit ÷ Revenue | +81.0% | — | +48.2% | +38.8% | +67.1% |
| Operating MarginEBIT ÷ Revenue | +10.2% | — | -3.3% | -58.6% | +20.9% |
| Net MarginNet income ÷ Revenue | +7.9% | — | -2.0% | -61.9% | +19.4% |
| FCF MarginFCF ÷ Revenue | +17.0% | — | +15.8% | -38.9% | +22.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -33.1% | — | +39.0% | -99.9% | +4.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.4% | +7.7% | +126.3% | -52.4% | +6.1% |
Valuation Metrics
MDXG leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 11.5x trailing earnings, MDXG trades at a 55% valuation discount to ILMN's 25.5x P/E. On an enterprise value basis, MDXG's 5.1x EV/EBITDA is more attractive than ILMN's 19.6x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $548M | $366M | $1.1B | $225M | $21.1B |
| Enterprise ValueMkt cap + debt − cash | $405M | $384M | $1.1B | $238M | $22.2B |
| Trailing P/EPrice ÷ TTM EPS | 11.53x | -6.13x | -53.60x | -3.33x | 25.45x |
| Forward P/EPrice ÷ next-FY EPS est. | 295.20x | — | 22.85x | — | 26.77x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 6.01x |
| EV / EBITDAEnterprise value multiple | 5.14x | — | — | — | 19.58x |
| Price / SalesMarket cap ÷ Revenue | 1.31x | — | 2.92x | 1.96x | 4.86x |
| Price / BookPrice ÷ Book value/share | 2.15x | 2.32x | 3.77x | 0.67x | 7.95x |
| Price / FCFMarket cap ÷ FCF | 7.51x | — | 30.66x | — | 22.63x |
Profitability & Efficiency
MDXG leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
ILMN delivers a 32.8% return on equity — every $100 of shareholder capital generates $33 in annual profit, vs $-35 for NAUT. OSUR carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ILMN's 0.94x. On the Piotroski fundamental quality scale (0–9), ILMN scores 8/9 vs NAUT's 1/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +12.9% | -35.0% | -2.6% | -15.1% | +32.8% |
| ROA (TTM)Return on assets | +9.7% | -29.2% | -1.9% | -12.8% | +13.4% |
| ROICReturn on invested capital | +42.3% | -26.0% | -5.7% | -20.0% | +16.8% |
| ROCEReturn on capital employed | +25.7% | -32.0% | -5.8% | -16.8% | +17.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 1 | 5 | 3 | 8 |
| Debt / EquityFinancial leverage | 0.09x | 0.19x | 0.06x | 0.04x | 0.94x |
| Net DebtTotal debt minus cash | -$144M | $18M | -$46M | $13M | $1.1B |
| Cash & Equiv.Liquid assets | $166M | $12M | $65M | $199,278 | $1.4B |
| Total DebtShort + long-term debt | $23M | $30M | $20M | $13M | $2.6B |
| Interest CoverageEBIT ÷ Interest expense | 25.32x | — | — | — | 12.09x |
Total Returns (Dividends Reinvested)
CDNA leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ILMN five years ago would be worth $3,717 today (with dividends reinvested), compared to $2,759 for CDNA. Over the past 12 months, NAUT leads with a +311.5% total return vs MDXG's -47.1%. The 3-year compound annual growth rate (CAGR) favors CDNA at 37.7% vs OSUR's -23.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -43.1% | +50.8% | +12.0% | +31.5% | +3.2% |
| 1-Year ReturnPast 12 months | -47.1% | +311.5% | +45.2% | +12.2% | +81.7% |
| 3-Year ReturnCumulative with dividends | -36.6% | +21.0% | +161.1% | -55.2% | -27.1% |
| 5-Year ReturnCumulative with dividends | -62.9% | -71.3% | -72.4% | -68.3% | -62.8% |
| 10-Year ReturnCumulative with dividends | -48.5% | -72.4% | +385.1% | -53.1% | +0.7% |
| CAGR (3Y)Annualised 3-year return | -14.1% | +6.6% | +37.7% | -23.5% | -10.0% |
Risk & Volatility
Evenly matched — MDXG and CDNA each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDXG is the less volatile stock with a 1.22 beta — it tends to amplify market swings less than NAUT's 1.82 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CDNA currently trades 92.3% from its 52-week high vs MDXG's 46.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 1.82x | 1.39x | 1.45x | 1.23x |
| 52-Week HighHighest price in past year | $7.99 | $4.31 | $23.24 | $3.82 | $155.53 |
| 52-Week LowLowest price in past year | $3.02 | $0.62 | $10.96 | $2.08 | $73.86 |
| % of 52W HighCurrent price vs 52-week peak | +46.2% | +66.8% | +92.3% | +81.9% | +89.2% |
| RSI (14)Momentum oscillator 0–100 | 49.3 | 52.5 | 56.4 | 47.1 | 65.2 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 315K | 667K | 473K | 1.5M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: MDXG as "Buy", NAUT as "Buy", CDNA as "Buy", OSUR as "Hold", ILMN as "Buy". Consensus price targets imply 171.0% upside for MDXG (target: $10) vs -13.2% for NAUT (target: $3).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $10.00 | $2.50 | $24.00 | $4.00 | $147.38 |
| # AnalystsCovering analysts | 15 | 5 | 13 | 13 | 50 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 2 | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | 0.0% | +7.9% | +6.7% | +3.5% |
MDXG leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). ILMN leads in 1 (Income & Cash Flow). 1 tied.
MDXG vs NAUT vs CDNA vs OSUR vs ILMN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MDXG or NAUT or CDNA or OSUR or ILMN a better buy right now?
For growth investors, MiMedx Group, Inc.
(MDXG) is the stronger pick with 20. 0% revenue growth year-over-year, versus -38. 1% for OraSure Technologies, Inc. (OSUR). MiMedx Group, Inc. (MDXG) offers the better valuation at 11. 5x trailing P/E (295. 2x forward), making it the more compelling value choice. Analysts rate MiMedx Group, Inc. (MDXG) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MDXG or NAUT or CDNA or OSUR or ILMN?
On trailing P/E, MiMedx Group, Inc.
(MDXG) is the cheapest at 11. 5x versus Illumina, Inc. at 25. 5x. On forward P/E, CareDx, Inc is actually cheaper at 22. 8x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — MDXG or NAUT or CDNA or OSUR or ILMN?
Over the past 5 years, Illumina, Inc.
(ILMN) delivered a total return of -62. 8%, compared to -72. 4% for CareDx, Inc (CDNA). Over 10 years, the gap is even starker: CDNA returned +385. 1% versus NAUT's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MDXG or NAUT or CDNA or OSUR or ILMN?
By beta (market sensitivity over 5 years), MiMedx Group, Inc.
(MDXG) is the lower-risk stock at 1. 22β versus Nautilus Biotechnology, Inc. 's 1. 82β — meaning NAUT is approximately 49% more volatile than MDXG relative to the S&P 500. On balance sheet safety, OraSure Technologies, Inc. (OSUR) carries a lower debt/equity ratio of 4% versus 94% for Illumina, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MDXG or NAUT or CDNA or OSUR or ILMN?
By revenue growth (latest reported year), MiMedx Group, Inc.
(MDXG) is pulling ahead at 20. 0% versus -38. 1% for OraSure Technologies, Inc. (OSUR). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -261. 5% for OraSure Technologies, Inc.. Over a 3-year CAGR, MDXG leads at 16. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MDXG or NAUT or CDNA or OSUR or ILMN?
Illumina, Inc.
(ILMN) is the more profitable company, earning 19. 6% net margin versus -59. 8% for OraSure Technologies, Inc. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -59. 2% for OSUR. At the gross margin level — before operating expenses — MDXG leads at 82. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MDXG or NAUT or CDNA or OSUR or ILMN more undervalued right now?
On forward earnings alone, CareDx, Inc (CDNA) trades at 22.
8x forward P/E versus 295. 2x for MiMedx Group, Inc. — 272. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MDXG: 171. 0% to $10. 00.
08Which pays a better dividend — MDXG or NAUT or CDNA or OSUR or ILMN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is MDXG or NAUT or CDNA or OSUR or ILMN better for a retirement portfolio?
For long-horizon retirement investors, CareDx, Inc (CDNA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+385.
1% 10Y return). Nautilus Biotechnology, Inc. (NAUT) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CDNA: +385. 1%, NAUT: -72. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MDXG and NAUT and CDNA and OSUR and ILMN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MDXG is a small-cap high-growth stock; NAUT is a small-cap quality compounder stock; CDNA is a small-cap quality compounder stock; OSUR is a small-cap quality compounder stock; ILMN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.